Home › Research › Inflammation and the immune system
Tau and neuroinflammation: What impact for Alzheimer's Disease and Tauopathies?
Laurent C, Buée L, Blum D.. Biomedical journal, 2018-02-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer's Disease (AD) is a chronic neurodegenerative disorder and the most common type of dementia (60-80% of cases). In 2016, nearly 44 million people were affected by AD or related dementia. AD is characterized by progressive neuronal damages leading to subtle and latter obvious decline in cognitive functions including symptoms such as memory loss or confusion, which ultimately require full-time medical care.
What this study adds
Evidence grade: Low
This is a narrative review. This review links tau, neuroinflammation and Alzheimer's disease and notes how many people are affected. It summarizes existing knowledge rather than testing a treatment, so it does not show that any therapy works.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Laurent, C., Buée, L., & Blum, D. (2018). Tau and neuroinflammation: What impact for Alzheimer's Disease and Tauopathies? Biomedical journal. https://doi.org/10.1016/j.bj.2018.01.003
Vancouver
Laurent C, Buée L, Blum D. Tau and neuroinflammation: What impact for Alzheimer's Disease and Tauopathies? Biomedical journal. 2018. doi:10.1016/j.bj.2018.01.003. PMID: 29673549.
BibTeX
@article{laurent2018-29673549,
author = {Laurent, C. and Buée, L. and Blum, D.},
title = {{Tau and neuroinflammation: What impact for Alzheimer's Disease and Tauopathies?}},
journal = {Biomedical journal},
year = {2018},
doi = {10.1016/j.bj.2018.01.003},
pmid = {29673549},
url = {https://doi.org/10.1016/j.bj.2018.01.003}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- In 2016, nearly 44 million people were affected by AD or related dementia.
- AD is characterized by progressive neuronal damages leading to subtle and latter obvious decline in cognitive functions including symptoms such as memory loss or confusion, which ultimately require full-time medical care.
- Its neuropathology is defined by the extracellular accumulation of amyloid-β (Aβ) peptide into amyloid plaques, and intraneuronal neurofibrillary tangles (NFT) consisting of aggregated hyper- and abnormal phosphorylation of tau protein.
- The latter, identified also as Tau pathology, is observed in a broad spectrum of neurological diseases commonly referred to as "Tauopathies".
Why it matters
This review links tau, neuroinflammation and Alzheimer's disease and notes how many people are affected. It summarizes existing knowledge rather than testing a treatment, so it does not show that any therapy works.
Study details
- Evidence strengthLow
How this study scored 51/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Biomedical journal) |
| Journal's citation record | 0 / 4 | Biomedical Journal: journal h-index 70 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2018 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 347 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 34.7 citations a year over 10 year(s) since 2018 |
| Impact for its field and year | 5 / 6 | Cited 26.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 15 other studies in this library |
| Still being cited | 3 / 4 | Cited 85 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author David L Blum: h-index 63 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Inserm: institution h-index 1,988 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 29673549) |
| Free to read | 2 / 2 | Free to read |
| Total | 51 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.bj.2018.01.003
- PubMed: 29673549
- Original source →
- Free full text: Biomedical Journal →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 35.
Later studies that cite this one
15 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Inflammation and the immune system from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.